Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)

被引：0
|
作者：
S G Louie
B Ely
H-J Lenz
K S Albain
C Gotay
D Coleman
D Raghavan
A F Shields
P J Gold
C D Blanke
机构：
[1] University of Southern California,Department of Pharmacy
[2] Norris Comprehensive Cancer Center,Department of Oncology
[3] Loyola University Chicago/Cardinal Bernardin Cancer Center,undefined
[4] University of British Columbia,undefined
[5] Cancer Research Center of Hawaii,undefined
[6] Carolinas Medical Center/Levine Cancer Institute,undefined
[7] Karmanos Cancer Institute/Wayne State University,undefined
[8] Swedish Cancer Institute,undefined
[9] Knight Cancer Institute and SWOG,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
elderly; pharmacokinetics; colorectal cancer; capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1744 / 1749
页数：5
相关论文
共 50 条
  • [31] Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer
    Vincent, Mark D.
    Breadner, Daniel
    Soulieres, Denis
    Kerr, Ian G.
    Sanatani, Michael
    Kocha, Walter
    Klimo, Peter
    MacKenzie, Mary J.
    O'Connell, Anne
    Whiston, Frances
    Malpage, Anne S.
    Stitt, Larry
    Welch, Stephen A.
    FUTURE ONCOLOGY, 2017, 13 (09) : 777 - 786
  • [32] Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer
    Larsen, Finn Ole
    Boisen, Mogens Karsbol
    Fromm, Annelene L.
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2012, 51 (02) : 231 - 233
  • [33] Effectiveness of gemcitabine and capecitabine in advanced colorectal cancer patients: A retrospective analysis.
    Salgado, Mercedes
    Reboredo, Margarita
    Medina, Ana
    Quintero, Guillermo
    Pellon, Maria Luz
    Reinoso, Carlos Romero
    Jorge, Monica
    Fernandez-Montes, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [34] Genotyping to predict for response and toxicity to capecitabine in advanced colorectal cancer patients (pts).
    Sharma, R
    Hoskins, J
    Beale, P
    Li, K
    Clarke, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 130S - 130S
  • [35] Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC)
    Ahn, JB
    Jung, KH
    Park, YS
    Kim, YH
    Chang, HJ
    Sohn, DK
    Lim, SB
    Choi, HS
    Jeong, SY
    Park, JG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 299S - 299S
  • [36] Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer
    El-Rayes B
    Shields, A.
    Zalupski, M.
    Bekaii-Saab, T.
    Heilbrun, L.
    Vaishampayan, U.
    Manza, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [37] XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).
    López-Gómez, L
    Escudero, P
    Yubero, A
    Feliú, J
    Salud, A
    Galán, A
    Bolaños, M
    Vicent, JM
    Losa, F
    González-Barón, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [38] Capecitabine in advanced colorectal cancer: A low toxicity schedule
    Frisia, Nicola
    Onida, Francesco
    Galassi, Barbara
    Tomirotti, Maurizio
    ANNALS OF ONCOLOGY, 2004, 15 : 100 - 100
  • [39] Capecitabine for locally advanced and metastatic colorectal cancer:A review
    Georgios V Koukourakis
    Georgios Zacharias
    John Tsalafoutas
    Dimitrios Theodoridis
    Vassilios Kouloulias
    World Journal of Gastrointestinal Oncology, 2010, (08) : 311 - 321
  • [40] Capecitabine for locally advanced and metastatic colorectal cancer: A review
    Koukourakis, Georgios V.
    Zacharias, Georgios
    Tsalafoutas, John
    Theodoridis, Dimitrios
    Kouloulias, Vassilios
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 2 (08) : 311 - 321
12345